Press release
Investigation announced for Investors in shares of Novartis AG (NYSE: NVS)
An investigation for investors in Novartis AG (NYSE: NVS) shares over potential securities laws violations by Novartis AG.
Investors who purchased shares of Novartis AG (NYSE: NVS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Novartis AG regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Switzerland based Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Novartis AG reported that its annual Total Revenue declined from over $53.16 billion in 2018 to over $48.67 billion in 2019, and that its Net Income declined from over $12.61 billion in 2018 to as low as $11.73 billion in 2019.
On June 25, 2020, Novartis AG agreed to pay $225 million in criminal fines and disgorge $112 million in settling bribery allegations brought forth by the U.S. Department of Justice and the Securities and Exchange Commission. Novartis AG was under investigation for claims that: (1) the Company had bribed doctors and hospitals in Greece to prescribe “Novartis-branded pharmaceuticals”; (2) the Company had paid bribes in Vietnam to advance their business; and (3) the Company had falsified their financial records to conceal said activities.
Shares of Novartis AG (NYSE: NVS) closed on July 14, 2020, at $87.47 per share.
Those who purchased shares of Novartis AG (NYSE: NVS) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Novartis AG (NYSE: NVS) here
News-ID: 2090059 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Novartis
Pazopanib Market Analysis By Top Keyplayers - Novartis, GlaxoSmithKline, Novarti …
The "Pazopanib Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Pazopanib Market, 2024-2031
Verified Market Research's most recent report, "Pazopanib Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination of the…
Onychomycosis Market to Register Incremental Growth During the Forecast Period ( …
DelveInsight's "Onychomycosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Onychomycosis, historical and forecasted epidemiology as well as the Onychomycosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Onychomycosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Onychomycosis Market Forecast
https://www.delveinsight.com/sample-request/onychomycosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Onychomycosis…
(2023-2031) Acromegaly Market | Novartis AG, Ipsen Pharma
[100 pages] Report "Acromegaly Market" detailed analysis of a business is mainly segmented by Application, by Type, Region (North America, Europe, Asia-Pacific, South America, and Middle East & Africa), manufacture and Forecast to 2031.
"Final Report will add the analysis of the impact of COVID-19 on this industry."
Global "Acromegaly Market" report analyses the best market prospects and lists the characteristics that are and will continue to propel the development of the…
Rydapt Market 2020 Clinical Analysis – Novartis
Global Rydapt Market Growth 2020-2025
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Rydapt Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought…
Global HER2-negative breast cancer Treatment Market to 2025| AstraZeneca, Bristo …
Researchmoz added Most up-to-date research on "Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2019-2025" to its huge collection of research reports.
HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.
In 2018, the global HER2-negative breast cancer Treatment…
Nilotinib Market Report 2018 – 2023: Novartis
The Study Paper in this Global Nilotinib Market includes Novartis.
Get Free Sample Brochure of Nilotinib Market spread across [142 pages] @ https://www.marketgrowthinsight.com/sample/4896
Unbiased perspective on intangible aspects such as key challenges, threats, new entrants as well as strengths and weaknesses of the prominent vendors too are…
